medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

COVID-19 Network Model to Evaluate Vaccine Strategies towards Herd
Immunity
Josephine N. A. Tetteh1,4 , Van Kinh Nguyen2 and Esteban A. Hernandez-Vargas1,3,âˆ—
1 Frankfurt

Institute for Advanced Studies, Frankfurt am Main, Germany

2 Imperial

College London, London, United Kingdom

3 Instituto

de MatemÃ¡ticas, Universidad Nacional Autonoma de Mexico, Boulevard Juriquilla

3001, Santiago de QuerÃ©taro, Qro., 76230, MÃ©xico
4 Institut

fÃ¼r Mathematik, Goethe-UniversitÃ¤t, Frankfurt am Main, Germany

âˆ— Corresponding

author

Email: vargas@fias.uni-frankfurt.de

Abstract
With more than 60 million confirmed cases and more than 1.5 million deaths, SARS-CoV-2
has paralyzed our societies, leading to self isolation and quarantine for several months. A
COVID-19 vaccine remains a critical element in the eventual solution to this public health
crisis. Two vaccines are ready to be mass produced and eventually supplied to the population.
Here, we develop an epidemiological network model able to represent COVID-19 pandemic
dynamics of different countries such as in Italy. Stochastic computational simulations identify
the necessary number of vaccines and vaccine efficacy thresholds capable of preventing an
epidemic whilst adhering to lockdown guidelines. Assuming a vaccine efficacy of 100% in a
mass vaccination program, at least 60% of a given population should be vaccinated to obtain
herd immunity. Otherwise, new waves of COVID-19 would be reported. However, reaching
60% of the population will be an unprecedented mass immunisation campaign that will take
several months and millions of dollars. If the vaccine efficacy reports lower levels of efficacy
in practice, then the coverage of vaccination would be needed to be even higher. Simulations
suggest that the "Ring of Vaccination" strategy, vaccinating susceptible contact and contact
of contacts, would be a more tractable vaccine strategy to prevent the new waves of COVID
-19 meanwhile a high percent of the population is vaccinated.

1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

1

Introduction

The novel Coronavirus SARS-CoV-2 epidemic which first emerged from Wuhan, China in December 2019 has spread globally, causing high levels of mortality and morbidity worldwide. To
curb the spread, governments across the world have implemented measures ranging from quarantining, social distancing, wearing of face masks among others. Amidst this crisis, national
health care systems such as in Italy and the United States of America have been overwhelmed
by the ever-increasing number of infection cases [36].
COVID-19 epidemiological models have been formulated to understand and curb the spread
of the disease. Many of these models follow an SIR framework either in the deterministic or
stochastic form or both [2, 59, 53, 55, 9, 10]. Other variations and modifications to this
general model have been considered including SEIR [47, 30, 50] and SIRD [13] compartmental
models. Some models also include parameters such as age-heterogeneity [56], guiding the flow
of users in supermarkets [19], and governmental policies [50, 4, 32]. In addition, a few studies
incorporate the dynamics of the disease within an individual host [21, 1]. However, only a few
of these models, currently predicting the SARS-CoV-2 pandemic, consider the structure of the
population and the underlying interactions between individuals [15, 61, 22].

social network
ct
conta

infected

vaccine

vaccinated

Figure 1: Model scheme. An illustration of infection spread with vaccination on a social
network. Individuals in the social network are considered as nodes and contact between nodes
exposed to the virus and those who do not have the virus can potentially lead to a transmission.
Persons who are vaccinated are considered to be immune to infection. The epidemic state of
each node is represented by a colour: Susceptibles, S, (â€¢), Exposed, E, (â€¢), Infected, I, (â€¢),
Vaccinated, V, (â€¢) and Recovered, R, (â€¢).
The assumption of random homogeneous mixing in epidemiological models has been doc2

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

umented to be unrealistic in nature as populations have underlying structural properties and
individuals tend to interact with each other [14]. Increasingly, network theory is being used in
epidemiology [35, 26, 51, 16]. In particular, social networks have gained popularity in conceptualising the effects of social interaction during epidemics in a given population [38, 25, 54].
Contacts between individuals in a given population can be captured in a network where nodes
represent individuals and the edges represent the connections between them [20]. Social networks are thus important determinants of infectious disease transmission as for example, infections transmitted by close contact can easily spread along the paths of a network.
With the continuation of SARS-CoV-2 in many parts of the world, the push for a vaccine
has become highly necessary. Pharmaceutical companies are in a race to develop suitable
vaccines as there is a lack of other alternatives. As of October 2020, there were 17 candidate
vaccines undergoing trial at various stages. Owing to the fact that it is a novel viral disease, it
is still unclear what levels of vaccine efficacies will be sufficient to curb the spread of the virus.
Identifying such efficacies earlier can direct vaccine development and administration in the
population [23]. Previous studies suggest that vaccination would be effective for protecting
the host against SARS-CoV-2 [28], however, there have not been studies to evaluate the
potential effects of different vaccination programs over a network model.
A key question to be answered is, how much vaccine is required to create herd immunity to
block SARS-CoV-2 transmission? [3]. In other words, how many people need to be vaccinated
in order to reach herd immunity? Here, we employ a network-based approach to explore
the potentials of two vaccination schemes, classical mass vaccination and ring vaccination,
in minimizing the spread of SARS-CoV-2, see Figure 1. Ring vaccination is a vaccination
strategy in which infected cases and contacts of cases are identified and vaccinated [18, 39].
Our analysis uses a stochastic network simulation model of SARS-CoV-2 transmission to
examine its control by mass and ring vaccination strategies with varying efficacies in the
presence of non-pharmaceutical disease control interventions. Given that vaccinating millions
of people will require a lot of time, this study implements a lockdown period as a further
control measure during vaccination strategies in our simulations. The main objective is to
identify the necessary vaccine efficacy thresholds capable of preventing an epidemic whilst
adhering to lockdown instructions.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 1: Definition of key terms and parameters
Key term
N
hki
transmission
probability Î²
incubation period
infection period
vaccine efficacy Î·
%vac
T
%exposed

2

Definition
number of nodes in the network
average degree distribution of nodes in the
network
the probability that infection is spread due to
contact between an infected node and a
susceptible node
the interval between exposure to virus and
initial occurrence of symptoms
interval between symptom onset to recovery
efficacy of vaccine
percentage of population vaccinated prior to
infection (before case zero)
epidemic duration
percentage of population exposed to virus
before onset of vaccination

Value
106
10
Eqn (1)

1 âˆ’ 5 days
6 âˆ’ 19 days
varies
varies
360 days
varies

Modelling Epidemic Spread on Networks

2.1

Model Setup

Network Generation. To study the impact of vaccination on the epidemic dynamics of
SARS-CoV-2, the underlying structure of human interactions is represented by a typical complex network. As heterogeneous networks are often used to explore epidemic spread, we
consider the infection dynamics on an Erdos-Renyi (ER) network due to its tractability and
practicability [27, Chapter 1]. The ER network is based on the G(n, M ) random graph model
characterized by two parameters; the network size n and the number of edges M which assigns exactly M number of edges to each graph. In the ER networks used for this study,
n = N, M = 5N, that is G(N, 5N ), which yields an average degree distribution hki = 10.
Epidemic Spread. SARS-CoV-2 is a disease which spreads primarily through close
contact with an infected person. Following the exposure to the SARS-CoV-2 virus and before
symptom onset, individuals go through an incubation period of about 14 days with the average
being about 5 âˆ’ 6 days [33, 52, 7]. After this incubation period, infected individuals become
symptomatic and are able to transmit to others through respiratory droplets or by direct
contact [33].
Epidemic States. We simulated a Susceptible - Exposed - Infected - Recovered - Vaccinated (SEIRV) process on an Erdos-Renyi network with N = 106 nodes. At any instant during
the infection process, the status of a node can be in any one of five possible states: Susceptible
(S, not infected but can be infected), Exposed (E, infectious, may not show symptoms and

4

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

can transmit to others), Infected (I, infectious and symptomatic, capable of transmission to
others), Recovered (R , recovered and immune to the disease) and Vaccinated (V , vaccinated).
Therefore, at any time, t, in the infection process, N (t) = S(t) + E(t) + I(t) + R(t) + V (t).
Epidemic Process. The model (depicted in Algorithm 1 proceeds in discrete one-day
time steps for a period of 360 days to determine disease dynamics. Simulation codes can be
found in Supplemental Materials. At the initial state of the epidemic process, all individuals
in the network are susceptible except one (patient zero) which is in the exposed state. On each
day during the epidemic process, there is interaction between individuals and infected persons
can potentially transmit to their susceptible contacts. If a susceptible individual comes into
contact with someone who has the virus (that is, a person in the E or I state), a Binomial
trial is used to determine if the contact results in an infection. If yes, the newly infected
susceptible individual moves from the S state to the E state. Any individual exposed to the
disease remains in the E state for the duration of the incubation period after which it moves
to the I state. Infectious individuals can transmit to their neighbours, when they come into
contact, in Binomial trial with a given probability, Î²(t) and then move into the R state after
the infectious period.
In the course of an epidemic, the rate of infection is never constant. As interventions are
being executed, the rate of infection decreases, otherwise it increases. To model this response,
we utilise a double logistic function to model the various phases of the infection dynamics
leading to a decline in cases when interventions are initiated and a resurgence in cases when
interventions cease. The double logistic function used to define a time dependent probability
of infection, Î²(t) is as follows:

Î²(t) = b1 + (b2 âˆ’ b1 ) âˆ’1 +

1
âˆ’r
(tâˆ’m
)
1
1
1+e
+ 1 + eâˆ’r2 (tâˆ’m2 )


(1)

where b1 is the first boundary (i.e. function value at time zero), b2 is the second boundary, r1
is the rate of change of first period, r2 is rate of change of second period, m1 is the midpoint
of the first period (start of interventions), m2 is the midpoint of the second period (end
of interventions) and t is time. Note that if b1 > b2 the function increases first and then
decreases, and vice versa. To get a good set of parameters for Î²(t), we applied Eqn (1) to
emulate infection data (from February 22 to September 1 2020) from Italy, one of the worst
hit countries during the SARS-CoV-2 pandemic.
The main goal of vaccination in this model is to block transmission. Every day, there
is contact between infected and vaccinated individuals. Vaccinated individuals that become
exposed due to contact with an exposed individual move into the E state with probability
(1 âˆ’ Î·)Î²(t), where Î· is the efficacy of the vaccine. Individuals for whom the vaccine is effective
remain in the V state whilst those for whom the vaccine is not effective move into the E state
and later into the I state after which they proceed to the R state. Furthermore, depending on
5

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the vaccination strategy being modelled, the time of vaccination as well as population coverage
varies.
Algorithm 1: Epidemic process on social network
Input: ER Network, Î²(t), epidemic duration, T = 360 days
Output: Number of nodes in each state after each simulation
Initialize: Choose an index case at random, and set state to be E. Set
V (0) = %vac, S(0) = N âˆ’ V (0), E(0) = 1, I(0) = 0, R(0) = 0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

for t âˆˆ T do
for n âˆˆ {e|State(e) = E} do
if incubation period is reached then
State(n) = I
for each neighbour, nb of n do
if State(nb) = S then
State(nb) = E with a binomial trial B(1, Î²(t))
if State(nb) = V then
State(nb) = E with a binomial trial B(1, (1 âˆ’ Î·) Ã— Î²(t))
for m âˆˆ {i|State(i) = I} do
for each neighbour, mnb of m do
if State(mnb) = S then
State(mnb) = E with a binomial trial B(1, Î²(t))
If the infectious period is reached, State(m) = R
Stop the simulation when there is no infectious node and update the number of
nodes in all states.
Result: Updated number of nodes in all states
For the first strategy which we refer to as the classical mass vaccination strategy, a frac-

tion of individuals start in the V state (denoted %vac) with one index case (patient zero) and
the rest in the S state. The population coverage in this case ranges from 10%, 20%, Â· Â· Â· , 100%.
The modelling process follows as in Algorithm 1.
For the second strategy which we refer to as ring vaccination, vaccination occurs after a
percentage (1% or 3%) of the population has been exposed to the virus during the epidemic. In
this case, we simulate the epidemics as described above (in Algorithm 1) with no vaccination
and only begin vaccine administration after a proportion of the population (%exposed) has
been exposed (See Algorithm 2 for more details). We assume that once a case is diagnosed,
all the contacts or neighbours are traceable and vaccinated. To initiate the ring vaccination,
susceptible contacts of exposed individuals can be vaccinated in a binomial trial with probability (1 âˆ’ Î·)Î²(t). This vaccination is further extended to susceptible contacts of these first
6

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

contacts with the assumption that contacts are identified through contact tracing. Contacts
of contacts are also vaccinated with the same probability. In our model, we also assume that
traced and identified susceptible contacts and contacts of contacts are vaccinated. This process
is described in Algorithm 2 and detailed implementation can be found at Code and examples.
In both strategies, we assume that the vaccine does not have an effect on infected or exposed
individuals. Table 1 summarizes all parameters and key terms used in this study.

2.2

Simulation Scenarios

Several scenarios are explored here. First, we consider an epidemic implemented with no
vaccination. This scenario is evident of the epidemic outcome without the discovery of a
vaccine. Subsequent scenarios consist of the overall performance of the vaccine by considering
its efficacy in preventing transmission and symptomatic infection using either the classical
mass vaccination or the ring vaccination strategy. In our simulations, vaccine efficacy varied
between 40% âˆ’ 100% whereas population coverage for classical vaccination varied between
10% âˆ’ 100%. For ring vaccination, the proportion of exposed individuals (%exposed) varied
as 1% and 3% (see Table 2). For all simulations: N = 106 , b1 = 0.028, b2 = 0.001, r1 = 0.09,
r2 = 0.04, m1 = day 50, m2 = day 126 and T = 360 days. Each scenario is repeated 50 times
and the mean of infection cases taken for analysis.

7

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Algorithm 2: Ring vaccination model on social network
Input: ER Network, Î²(t), epidemic duration, T = 360 days,%exposed
Output: Number of nodes in each state after each simulation
Initialize: Choose an index case (i) at random, and set state to be E. Set
V (0) = %vac, S(0) = N âˆ’ V (0), E(0) = 1, I(0) = 0, R(0) = 0
1
2
3
4
5
6
7
8
9

for t âˆˆ T do
if #{ e|State(e) = E} < %exposed then
proceed using Algorithm 1
else
for n âˆˆ {e|State(e) = E} do
if incubation period is reached then
State(n) = I
for each neighbour, nb of n do
if State(nb) = S then

10

State(nb) = E with a binomial trial, B(1, Î²(t))

11

select and store susceptible neighbours not exposed in previous step

12
13
14

and label as first contacts
if State(nb) = V then
State(nb) = E with a binomial trial, B(1, Î²(t))
for each node in first contacts do

15

vaccinate after 3 days

16

select and store susceptible neighbours and label as second contacts

17
18
19
20
21
22
23
24

for each node in second contacts do
vaccinate after 3 days
for m âˆˆ {i|State(i) = I} do
for each neighbour, mnb of m do
if State(mnb) = S then
State(mnb) = E with a binomial trial, B(1, Î²(t))
If the infectious period is reached, State(m) = R
Stop the simulation when there is no infectious node and update the number of
nodes in all states.
Result: Updated number of nodes in all states

8

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 2: Vaccination scenarios with corresponding population coverages and vaccine efficacies
considered in this study.
Scenario

Coverage

Time of vaccination

No vaccination
Mass
vaccination
Ring
vaccination

0%
10%, 20%, Â· Â· Â· , 100%

Before case zero

1st order and identified
contacts AND contacts
of contacts

After percentage of population
infected (varies between
1%, 3%)

2.3

Effect of
vaccine (%)
40, 60, 80, 100
40, 60, 80, 100

High-Performance Computing

Implementations of this network model was computationally demanding and challenging using
conventional resources. For instance, one simulation can take up to several hours or days to
complete in a modern desktop computer. Thus, due to these limitations, we employed a HighPerformance Computing (HPC) cluster for our simulations. The cluster used is FUCHS-CSC
from the Center for Scientific Computing (CSC, Frankfurt, Germany). It is based on 72 dualsocket AMD Magny-Cours CPU compute nodes with 64 GB of RAM, 250 dual-socket AMD
Istanbul compute nodes with 32 GB of RAM and 36 quad-socket AMD Magny-Cours compute
nodes with 128 GB of RAM each. A simulation in the HPC takes about 5h to complete for the
classical vaccination scenarios and about 5 âˆ’ 8 days for the ring vaccination scenarios. This
project is coded in Python.

3

Results

Our parameter fitting for Î²(t) shows infection peaks at comparable time points with varying
population percentages but essentially a qualitative fit of the data (see Figure 2). The parameter values used to fit Î²(t) are: b1 = 0.028, b2 = 0.001, r1 = 0.09, r2 = 0.04, m1 = 50,
m2 = 126.

9

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

 ( 5  Q H W Z R U N
 ' D W D   , W D O \ 

      

 ' D W D   , W D O \ 

 ( 5  Q H W Z R U N

Infected cases (%)

    
    

      

    

      

    

      

    

      

    
 

  

   

   

(days)
 7 LTime
 P H   G D \ V 

   

Figure 2: Comparism of infection cases between the network model simulation using Î²(t) and
Italian SARS-CoV-2 data from February 22 2020 to September 1 2020. The y-axis shows
the infection cases. Parameter values used are b1 = 0.028,b2 = 0.001, r1 = 0.09, r2 = 0.04,
m1 = 50, m2 = 126.

3.1

COVID-19 dynamics - control scenario

In a completely susceptible population, the introduction of one exposed individual leads to the
spread of the infection with more than one peak of cases of infection after some months. In
Figure 3, we see that the mean number of infected cases first peaks in the second month after
infection onset with about 12.8% of the population infected. By the fifth month during the
infection course, there arises a second peak of infected cases which closely matches the first.

10

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Infected cases (%)

50
40
30
20
10
0

0

1

2

3

4

5

6

Month

7

8

9 10 11

Figure 3: Illustration of the distribution of the final infected cases in different timing for a no
vaccination scenario. A population of N= 106 individuals was generated and 50 simulations
were run to simulate the epidemic in the course of one year. An individual was chosen randomly
as patient zero for each run. Circles represent mean infection cases for each month connected
by lines.

11

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 3: Average infection peak values considering vaccine efficacy and population coverage
No vaccination scenario
(control scenario)
12.79
Mass vaccination scenarios
(vaccination before case zero)
Population
Vaccine Efficacy
Coverage
40%
60%
80%
10%
12.67
11.72
13.37
20%
16.71
16.92
14.27
30%
12.68
10.81
9.54
40%
11.71
10.80
8.46
50%
6.50
4.18
4.29
60%
5.69
2.97
0.97
70%
1.55
1.07eâˆ’3
2.78eâˆ’4
80%
2.15âˆ’4
2.07eâˆ’4
1.20eâˆ’5
âˆ’5
90%
0
4.57
5.20eâˆ’6
100%
0
0
0
Ring vaccination scenarios
(population exposed before vaccination)
Vaccine Efficacy
40%
60%
80%
(1% of population exposed before vaccination)
0.95
0.95
1.03
(3% of population exposed before vaccination)
2.77
3.45
3.23

3.2

100%
14.33
16.27
10.45
6.48
2.33
0.10
5.01eâˆ’5
2.47eâˆ’5
8.67eâˆ’7
0

100%
0.97
3.06

Mass Vaccination Scenarios

These scenarios determine the outcome of vaccination at the initial stages of the epidemic
before infected cases peak. When vaccine efficacy is 40%, a population coverage of 50% or
more is needed to achieve infection peak with less than 10% infection cases. Table 3 reveals
that with vaccine efficacy of 60%, a coverage more than 70% and above keeps mean infection
cases on the low with elimination of the peak occurring when coverage is more than 80%.
Furthermore, low cases of infection are observed when 70% or more of the population is
vaccinated and vaccine efficacy is 80%. On the other hand, a vaccine which is 100% efficacious
requires 60% or more of the population to be vaccinated to ensure there is no peak of infections.
As seen in Figure 4 (see also Figure S1 - S4 in Supplementary Material), peak(s) of infection
cases are observed when a small percentage of the population is vaccinated. For instance, in
all scenarios, two infection peaks are observed when %vac is 40%. Similarly, there are peaks of
infection for vaccine coverage between 20% and 60% even when Î· varies. Therefore, vaccinating

12

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

a small proportion of the population is not useful in these instances as cases can still peak
even with a vaccine with 100% efficacy. Thus, the key to eliminating infection peaks is to
administer very efficacious vaccines to many individuals.

(a)

(b)

(c)

(d)

Figure 4: Outcome for mass vaccination scenarios for each vaccine efficacy percentage. This
shows the changes in mean infected cases over time under the different vaccine efficacies. In
(a), (b), (c) and (d) vaccine efficacies are 40%, 60%, 80% and 100% respectively.

3.3

Ring vaccination scenario

We carried out simulations using Algorithm 2 to determine the infection outcome when ring
vaccination is used. In Figure 5 (see also Figure S5 and Table 4), we show these outcomes with
varying scenarios of vaccine efficacy and when 1% or 3% of the population is already exposed to
the disease before the onset of vaccination. We see that there are less cases realised with a 1%
exposed population before the start of vaccination as compared to a 3% exposed population.
In addition, the number of infected cases in these scenarios are considerably lower than that of
the classical vaccination method. Also, even with a 100% efficacious vaccine, total eradication
of the peak is not achieved irrespective of the exposed population prior to vaccination (See
also Figure S5a and Figure S5b). Furthermore, only one peak of infection is seen using this
strategy compared to the sometimes two peaks of the mass vaccination strategy.

13

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 4: Average population coverage (in %) for ring vaccination scenarios considering vaccine
efficacy.
Vaccine Efficacy
40%
60%
80%
(1% of population exposed before vaccination)
35.94
36.32
36.30
(3% of population exposed before vaccination)
59.90
60.47
59.54

100%
36.57
57.38

In comparison to mass vaccination, a lower percentage of the population has to be vaccinated when using a ring vaccination protocol in order to attain low infection cases (see
Table 4). This is especially so as with effective contract tracing, more individuals can be
vaccinated and thus decreasing the number of infections. It is worth noting also that even
with the above results, the percentage of vaccinated individuals is lesser when only 1% of the
population is exposed prior to vaccination than when the prior exposed population is 3%.
Also, from Table 4 we see that the vaccinated populations are very similar in both scenarios
respectively irrespective of the efficacy of the vaccine.

(a) Ring vaccination when 1% of the population is exposed before the onset of vaccination.

(b) Ring vaccination when 3% of the population is exposed before the onset of vaccination.

Figure 5: Outcome for ring vaccination when 1% and 3% of the population has been exposed
before the onset of vaccination considering varying vaccine efficacy (Î· = 40%, 60%, 80%, 100%).

4

Discussion

With the ongoing spread of SARS-CoV-2 worldwide, pharmaceutical companies have also been
in a race to produce safe and highly effective vaccines to counter transmission of the disease.
As of December 2020, there were 52 vaccine candidates in clinical trials in humans, 13 of which
are in Phase 3 trials (see Table 5) [60]. In November 2020, some pharmaceutical companies
and institutes, including Pfizer Inc and BioNTech, Moderna, the University of Oxford (in
collaboration with AstraZeneca), announced positive results from the first interim analyses
of their Phase 3 vaccine trials [46, 48, 37]. Initial data released from these trials report that
the vaccines manufactured by Pfizer Inc/BioNTech and Moderna both yielded 95% efficacy
14

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

whereas that by University of Oxford (in collaboration with AstraZeneca) yielded 70% efficacy.
On 2 December 2020, the UK medicines regulator MHRA granted a temporary regulatory
approval for the Pfizer-BioNTech vaccine [43] which was under evaluation for emergency use
authorization (EUA) status by the United States Food and Drug Administration [57] and
approved for use on 11 December 2020 [43] in the United States.

15

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Table 5: List of candidate vaccines in Phase 3 trials of clinical evaluation. Adapted from [60].
SARS-CoV-2
Vaccine
Manufacturer /
Developer
University of
Oxford/AstraZeneca

Vaccine
platform

Timing of
doses

Route of administration

Status

0, 28 days

Intramuscular

Sinovac

Nonreplicating
viral vector
Inactivated

0.14 days

Intramuscular

Under review in
U.K and Australia
[17]
Limited use in
China [42]

Janssen
Pharmaceutical
Companies
Moderna/NIAID

Nonreplicating
viral vector
RNA

0, 56 days

Intramuscular

0, 28 days

Intramuscular

Wuhan Institute of
Biological
Products/Sinopharm
BioNTech/Fosun
Pharma/Pfizer

Inactivated

0, 14 days

Intramuscular

RNA

0, 21 days

Intramuscular

Beijing Institute of
Biological
Products/Sinopharm
Bharat Biotech
CanSino Biological
Inc./Beijing Institute
of Biotechnology
Novavax

Inactivated

0, 21 days

Intramuscular

Inactivated
Nonreplicating
viral vector
Protein
subunit
Nonreplicating
viral vector
Virus-like
particle
(VLP)
Protein
Subunit

0, 21 days

Intramuscular
Intramuscular

Gameleya Research
Institute
Medicago Inc.

Anhui Zhifei
Longcom
Biopharmaceutical,
Chinese Academy of
Sciences

0,21 days

Intramuscular

0,21 days

Intramuscular

0, 21 days

Intramuscular

0, 28, 56
days

Intramuscular

16

Under F.D.A.
review [43]

Approved in
Canada.
Emergency use in
U.S., U.K.,
U.A.E. [40, 41]

Limited use in
China [42]

Early use in
Russia [43]

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Although the Pfizer, Moderna and University of Oxford/AstraZeneca vaccines are expected
to be used worldwide in coming months, in other countries such as China and Russia, other
vaccines (from Sinovac in China and Gameleya Research Institute in Russia) have been developed and are currently in limited use in these countries. Table 5 summarizes the candidate
vaccines under phase 3 trial and their current usage status as well as their manufacturers and
vaccine platform (that is, a system which uses certain basic components as the backbone but
is relatively flexible and can be adapted quickly to be used against different pathogens [24]).
In this study, we modelled the spread of SARS-CoV-2 infection using an SEIRV model
structure on a social network. We run stochastic simulations to determine vaccine efficacy and
population coverage limits capable of extinguishing the disease. We considered two vaccination
strategies, each with varying scenarios regarding vaccine efficacy and population coverage. We
found that, the introduction of a single infected person into a completely susceptible population
leads to the spread of infection giving rise to more infected cases and subsequently more than
one infection peak. This is an indication that in the absence of a good enough vaccine, there
is a much higher chance of more than one infection peak which is already being observed in
some countries [8, 6].
In addition, the introduction of vaccination lowered the number of infected cases irrespective of the type of vaccination. Our simulations and analysis show that when using a mass
vaccination strategy, the lower the efficacy of the vaccine, the more people needed to be vaccinated against the disease in order to eliminate infection peak(s). For instance, a vaccine with
an efficacy of 40% will require more than 80% of the entire population to be vaccinated in
order to reach low infection peak values whereas a 100% effective vaccine will require more
than 60% of the population to be vaccinated. Given the experimental nature and limited
initial supply of vaccines, a classical mass vaccination campaign might not be feasible in many
countries. However, ring vaccination of likely case contacts and contacts of cases could provide
an effective alternative in distributing the vaccine to ensure low levels of infection and subsequently preventing infection peaks. This is with the assumption of effective contract tracing
of infected people.
Researchers, policy makers and the general public are of the opinion that the discovery of
a vaccine will allow the return to normality of life before the SARS-CoV-2 pandemic. It is
worth noting that, the discovery of a proven-to-be effective vaccine however, might not reduce
transmission completely. This is due to the fact that a vaccine which effectively reduces the
severity of transmission does not necessarily reduce virus transmission to a comparable degree.
It is also important to consider the potential impact of voluntary mass vaccination in the
efforts of clearing the epidemic [45, 49, 31, 11]. In years past, the roll-out of vaccination has
been faced with declining vaccine confidence in the general public which could possibly lead
to hesitancy in getting vaccinated [12]. Such instances could easily lead to a disruption of
people receiving a vaccine voluntarily thus, having a detrimental effect on efforts to eradicate
17

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the disease and hence such situations should not be underestimated.

Limitations and future work
Though exploring the effects of SARS-CoV-2 transmission on social networks, in this study we
have limited our analysis to one type of social network which is the Erdos-Renyi network. To
proceed towards increasing practicality, the analysis performed in this study can be extended to
consider disease spread and vaccination on other social networks, such as the BarabÃ¡siâ€“Albert
network [5] and small-world network [58] models, using similar scenarios and protocols. Such
network models can be compared with each other and the outcomes analysed. Data on known
social networks such as contact matrices and mixing patterns can also be used for further
analysis and evaluation.
Simulations in this study were performed with the assumption of an optimistic condition
in which there was vaccination of all contacts and contacts of contacts. In reality, contact
tracing is especially difficult in the course of an ongoing epidemic and thus reduces the impact
of vaccination efforts [34, 29]. Also, the model used here assumes there is equal mixing of
individuals and their neighbours in the network whereas in reality this is not the case and
consequently infection cases could be lower and population coverage may be reduced.
The model also assumes that all infected people recover from the disease and are immune.
The effect of mortality on the dynamics of the disease is not considered as this model aims
to study the general transmission dynamics and the effects of varying vaccination strategies.
Within-host dynamics such as the viral dynamics and immune responses would be important
to be included in a framework with higher resolution [44].
Epidemiological models of disease spread and transmission generally take into account
the reproduction number (R0 ) of the disease to gain knowledge on the transmission process.
Estimates of R0 vary widely as data continue to emerge in an ongoing epidemic. This study
however, does not examine this parameter since it does not directly impact the transmission
dynamics.
In summary, this study describes the transmission dynamics of SARS-CoV-2 on a social
contact network and the vaccine efficacy thresholds needed to prevent new waves of the disease.
For future work, we will focus on other network models and their analysis with respect to
SARS-CoV-2. We will also consider the transmission potential based on R0 and the dynamics
in this regard.

18

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Supplementary materials

30

20

10

30
25
20
15
10
5

0
1

2

3

4

5

6

Month

7

8

9

10

11

0

30
25
20
15
10
5

1

2

3

4

5

6

Month

7

8

9

10

0

11

1

2

3

4

5

6

7

8

9

10

11

5

6

7

8

9

10

11

Month

30
25
20
15
10
5

Infected cases (%)

%vac=40

Infected cases (%)

30

35

%vac=50

25
20
15
10
5

0

1

2

3

4

5

6

Month

7

8

9

10

0

11

Ã—10

1

2

3

4

5

6

Month

7

8

9

10

Infected cases (%)

%vac=70

12.5
10.0
7.5
5.0
2.5

15
10
5

0

11

Ã—10

3

7

15.0

%vac=60

20

0

0

0

Infected cases (%)

Infected cases (%)

%vac=30

35

0

0
0

Infected cases (%)

40

%vac=20

35

Infected cases (%)

Infected cases (%)

Infected cases (%)

40

%vac=10

40

%vac=80

6
5
4
3
2
1

1

2

3

4

Month

4

6

%vac=90

4
2
0
2
4
6

0

0.0
0

1

2

3

4

5

6

Month

7

8

9

10

0

11

Infected cases (%)

Ã—10

1

2

3

4

5

6

Month

7

8

9

10

11

0

1

2

3

4

5

6

Month

7

8

9

10

11

4

6

%vac=100

4
2
0
2
4
6
0

1

2

3

4

5

6

Month

7

8

9

10

11

Figure S1: Distribution of final infected cases in different timing for mass vaccination scenario
when Î· = 40%. Population coverage varies from 10% âˆ’ 100%. Circles represent mean infection
cases for each month connected by lines.

19

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

%vac=20

40

30
25
20
15
10
5

30

20

10

0
1

2

3

4

5

6

Month

7

8

9

10

11

0

1

2

3

4

5

6

7

Month

8

9

10

25
20
15
10
5

%vac=50

Ã—10

1

2

3

4

5

6

Month

7

8

9

10

15
10
5

2

Ã—10

1.0
0.8
0.6
0.4
0.2

1

2

3

4

5

6

Month

7

8

9

10

0

1

2

3

4

5

6

Month

7

8

9

10

5

6

7

8

9

10

11

5

6

7

8

9

10

11

Month

%vac=60

2.5

0

Ã—10

1

2

3

4

Month

3

1.4

%vac=80

5
4
3
2
1

%vac=90

1.2
1.0
0.8
0.6
0.4
0.2
0.0

0

Ã—10

Infected cases (%)

4

5.0

3

6

11

3

7.5

11

0

0.0

2

10.0

Infected cases (%)

Infected cases (%)

Infected cases (%)

%vac=70

1.2

1

12.5

7
1.4

5

0.0
0

11

10

15.0

0
0

15

17.5

20

0

20

0

Infected cases (%)

Infected cases (%)

Infected cases (%)

%vac=40

25

11

25
30

30

0

0
0

%vac=30

35

Infected cases (%)

%vac=10

35

Infected cases (%)

Infected cases (%)

40

1

2

3

4

5

6

Month

7

8

9

10

11

0

1

2

3

4

5

6

Month

7

8

9

10

11

4

6

%vac=100

4
2
0
2
4
6
0

1

2

3

4

5

6

Month

7

8

9

10

11

Figure S2: Distribution of final infected cases in different timing for mass vaccination scenario
when Î· = 60%. Population coverage varies from 10% âˆ’ 100%. Circles represent mean infection
cases for each month connected by lines.

20

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

30
20
10

30

20

10

35

Infected cases (%)

40

0

1

2

3

4

5

6

Month

7

8

9

10

20
15
10
5

1

2

3

4

5

6

Month

7

8

9

10

0

11

17.5

15
10
5

12.5
10.0

0

7.5
5.0
2.5
0.0

0
Ã—10

1

2

3

4

5

6

Month

7

8

9

10

11

Ã—10

1

2

3

4

5

6

Month

7

8

9

10

4
3
2
1
0
1

2

3

4

5

6

Month

7

8

9

10

%vac=80

2.0
1.5
1.0
0.5

7

8

9

10

11

5

6

7

8

9

10

11

4
2

0

1

2

3

4

Month

4

2.5

%vac=90

2.0
1.5
1.0
0.5
0.0

0

Ã—10

Infected cases (%)

6

3.0

2.5

11

5

Month

%vac=60

Ã—10

0.0
0

4

6

4

Infected cases (%)

Infected cases (%)

%vac=70

5

3

8

11

3.0
6

2

0
0

3

1

10

%vac=50

15.0

Infected cases (%)

%vac=40

20

Infected cases (%)

25

Infected cases (%)

25

0
0

11

%vac=30

30

0

0

Infected cases (%)

%vac=20

40

%vac=10

Infected cases (%)

Infected cases (%)

50

1

2

3

4

5

6

Month

7

8

9

10

11

0

1

2

3

4

5

6

Month

7

8

9

10

11

4

6
4

%vac=100

2
0
2
4
6
0

1

2

3

4

5

6

Month

7

8

9

10

11

Figure S3: Distribution of final infected cases in different timing for mass vaccination scenario
when Î· = 80%. Population coverage varies from 10% âˆ’ 100%. Circles represent mean infection
cases for each month connected by lines.

21

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

30

%vac=10

30
25
20
15
10
5

%vac=20

30
25
20
15
10

0

5

Infected cases (%)

35

35

Infected cases (%)

Infected cases (%)

40

20
15
10
5
0

0
0

1

2

3

4

5

6

Month

7

8

9

10

11

%vac=30

25

0

1

2

3

4

5

6

Month

7

8

9

10

0

11

1

2

3

4

5

6

7

8

9

10

11

5

6

7

8

9

10

11

Month

6

%vac=40

15

10

5

12

%vac=50

10
8
6
4
2
0

0
0

Ã—10

1

2

3

4

5

6

Month

7

8

9

10

3

Ã—10

1

2

3

4

5

6

Month

7

8

9

10

0.6
0.4
0.2

0

1

2

3

4

5

6

Month

7

8

9

10

Ã—10

%vac=80

3
2
1

1

2

3

4

Month

4

0.8

%vac=90

0.6
0.4
0.2
0.0

0

Ã—10

Infected cases (%)

1

1.0

4

11

2

4

0

0.0

3

0

Infected cases (%)

Infected cases (%)

%vac=70

%vac=60

4

11

5

0.8

5

0
0

11

1.0

Infected cases (%)

Infected cases (%)

Infected cases (%)

Infected cases (%)

20

1

2

3

4

5

6

Month

7

8

9

10

11

0

1

2

3

4

5

6

Month

7

8

9

10

11

4

6
4

%vac=100

2
0
2
4
6
0

1

2

3

4

5

6

Month

7

8

9

10

11

Figure S4: Distribution of final infected cases in different timing for mass vaccination scenario
when Î· = 100%. Population coverage varies from 10%âˆ’100%. Circles represent mean infection
cases for each month connected by lines.

22

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Î·= 40%

3.0

Infected cases (%)

Infected cases (%)

It is made available under a CC-BY 4.0 International license .

2.5
2.0
1.5
1.0
0.5
0.0

Î·= 60%

3.0
2.5
2.0
1.5
1.0
0.5
0.0

0

1

2

3

4

5

6

7

Month

8

9

10

11

0

1

2

3

4

5

6

7

Month

8

9

10

11

Î·= 80%

Infected cases (%)

Infected cases (%)

3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0

Î·= 100%

3.0
2.5
2.0
1.5
1.0
0.5
0.0

0

1

2

3

4

5

6

7

Month

8

9

10

11

0

1

2

3

4

5

6

7

Month

8

9

10

11

(a) Ring vaccination when 1% of the population is exposed before the onset of
vaccination.
8

Infected cases (%)

Infected cases (%)

8

Î·= 40%
6

4

2

4

2

0

0
0

1

2

3

4

5

6

Month

8

7

8

9

10

0

11

1

2

3

4

5

6

Month

8

Î·= 80%

Infected cases (%)

Infected cases (%)

Î·= 60%
6

6

4

2

7

8

9

10

11

10

11

Î·= 100%

6

4

2

0

0
0

1

2

3

4

5

6

Month

7

8

9

10

0

11

1

2

3

4

5

6

Month

7

8

9

(b) Ring vaccination when 3% of the population is exposed before the onset of
vaccination.

Figure S5: Illustrating number of infected cases when ring vaccination is employed and when
1% and 3% of the population has been exposed before the onset of vaccination considering
varying vaccine efficacies (Î· = 40%, 60%, 80%, 100%).

23

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

References
[1] A. E. S. Almocera, G. Quiroz, and E. A. Hernandez-Vargas. Stability analysis in covid19 within-host model with immune response. Communications in Nonlinear Science
and Numerical Simulation, page 105584, 2020. ISSN 1007-5704. doi: https://doi.org/
10.1016/j.cnsns.2020.105584. URL http://www.sciencedirect.com/science/article/
pii/S1007570420304147.
[2] R. M. Anderson, H. Heesterbeek, D. Klinkenberg, and T. D. Hollingsworth. How will
country-based mitigation measures influence the course of the COVID-19 epidemic? The
Lancet, mar 2020. ISSN 0140-6736. doi: 10.1016/S0140-6736(20)30567-5.
[3] R. M. Anderson, C. Vegvari, J. Truscott, and B. S. Collyer. Challenges in creating herd
immunity to SARS-CoV-2 infection by mass vaccination. The Lancet, 396(10263):1614â€“
1616, 2020. ISSN 1474547X. doi: 10.1016/S0140-6736(20)32318-7.
[4] A. Arenas, W. Cota, J. GÃ³mez-Gardenes, S. GÃ³mez, C. Granell, J. T. Matamalas,
D. Soriano-Panos, and B. Steinegger. A mathematical model for the spatiotemporal
epidemic spreading of covid19. medRxiv, 2020.
[5] A.-L. BarabÃ¡si. Linked: The new science of networks, 2003.
[6] E. Bontempi. The europe second wave of covid-19 infection and the italy â€œstrangeâ€ situation. Environmental Research, page 110476, 2020.
[7] R. M. Burke. Active monitoring of persons exposed to patients with confirmed covid19â€”united states, januaryâ€“february 2020. MMWR. Morbidity and mortality weekly report, 69, 2020.
[8] G. Cacciapaglia, C. Cot, and F. Sannino. Second wave covid-19 pandemics in europe: a
temporal playbook. Scientific reports, 10(1):1â€“8, 2020.
[9] G. C. Calafiore, C. Novara, and C. Possieri. A modified sirr model for the covid-19
contagion in italy. arXiv preprint arXiv:2003.14391, 2020.
[10] K. Chatterjee, K. Chatterjee, A. Kumar, and S. Shankar. Healthcare impact of covid19 epidemic in india: A stochastic mathematical model. Medical Journal Armed Forces
India, 2020.
[11] L. Z. Cooper, H. J. Larson, and S. L. Katz. Protecting public trust in immunization.
Pediatrics, 122(1):149â€“153, 2008.

24

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[12] A. de Figueiredo, C. Simas, E. Karafillakis, P. Paterson, and H. J. Larson. Mapping global
trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale
retrospective temporal modelling study. The Lancet, 396(10255):898â€“908, 2020.
[13] D. Fanelli and F. Piazza. Analysis and forecast of covid-19 spreading in china, italy and
france. Chaos, Solitons & Fractals, 134:109761, 2020.
[14] L. Ferretti, M. Cortelezzi, B. Yang, G. Marmorini, and G. Bianconi. Features and heterogeneities in growing network models. Physical Review E, 85(6):066110, 2012.
[15] J. A. Firth, J. Hellewell, P. Klepac, S. Kissler, A. J. Kucharski, and L. G. Spurgin. Using
a real-world network to model localized covid-19 control strategies. Nature medicine, 26
(10):1616â€“1622, 2020.
[16] W. M. Getz, R. Salter, and W. Mgbara. Adequacy of seir models when epidemics have
spatial structure: Ebola in sierra leone. Philosophical Transactions of the Royal Society
B, 374(1775):20180282, 2019.
[17] Government of Australia. Australiaâ€™s vaccine agreements. https://www.health.gov.au/
australias-vaccine-agreements, 2020. Accessed: 2020-12-12.
[18] D. Greenhalgh.

Optimal Control of An Epidemic By Ring Vaccination.

nications in Statistics. Stochastic Models, 2(3):339â€“363, 1986.

Commu-

ISSN 08820287.

doi:

10.1080/15326348608807041.
[19] G. Hernandez-Mejia and E. A. Hernandez-Vargas. When is sars-cov-2 in your shopping
list? Mathematical Biosciences, 328:108434, 2020. ISSN 0025-5564. doi: https://doi.org/
10.1016/j.mbs.2020.108434. URL http://www.sciencedirect.com/science/article/
pii/S0025556420301036.
[20] E. A. Hernandez-Vargas, A. Y. Alanis, and J. Tetteh. A new view of multiscale stochastic
impulsive systems for modeling and control of epidemics. Annual Reviews in Control,
2019.
[21] E. A. H. Hernandez-Vargas and J. X. Velasco-Hernandez. In-host modelling of covid-19
kinetics in humans. medRxiv, 2020.
[22] H. A. Herrmann and J.-M. Schwartz. Why covid-19 models should incorporate the network of social interactions. Physical Biology, 17(6):065008, 2020.
[23] S. H. Hodgson, K. Mansatta, G. Mallett, V. Harris, K. R. Emary, and A. J. Pollard.
What defines an efficacious covid-19 vaccine? a review of the challenges assessing the
clinical efficacy of vaccines against sars-cov-2. The Lancet Infectious Diseases, 2020.
25

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[24] H. K. C. Hume and L. H. Lua. Platform technologies for modern vaccine manufacturing.
Vaccine, 35(35):4480â€“4485, 2017.
[25] K. A. Kabir, K. Kuga, and J. Tanimoto. Effect of information spreading to suppress the
disease contagion on the epidemic vaccination game. Chaos, Solitons & Fractals, 119:
180â€“187, 2019.
[26] M. J. Keeling and K. T. Eames. Networks and epidemic models. Journal of the Royal
Society Interface, 2(4):295â€“307, 2005.
[27] F. Kepes. Biological networks, volume 3. World Scientific, 2007.
[28] F. Krammer. SARS-CoV-2 vaccines in development. Nature, 586(7830):516â€“527, 2020.
ISSN 14764687. doi: 10.1038/s41586-020-2798-3. URL http://dx.doi.org/10.1038/
s41586-020-2798-3.
[29] M. E. Kretzschmar, G. Rozhnova, M. C. Bootsma, M. van Boven, J. H. van de Wijgert,
and M. J. Bonten. Impact of delays on effectiveness of contact tracing strategies for
COVID-19: a modelling study. The Lancet Public Health, 5(8):e452â€“e459, 2020. ISSN
24682667. doi: 10.1016/S2468-2667(20)30157-2. URL http://dx.doi.org/10.1016/
S2468-2667(20)30157-2.
[30] A. J. Kucharski, T. W. Russell, C. Diamond, Y. Liu, J. Edmunds, S. Funk, R. M. Eggo,
F. Sun, M. Jit, J. D. Munday, et al. Early dynamics of transmission and control of
covid-19: a mathematical modelling study. The lancet infectious diseases, 2020.
[31] H. J. Larson, C. Jarrett, E. Eckersberger, D. M. Smith, and P. Paterson. Understanding
vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic
review of published literature, 2007â€“2012. Vaccine, 32(19):2150â€“2159, 2014.
[32] Q. Lin, S. Zhao, D. Gao, Y. Lou, S. Yang, S. S. Musa, M. H. Wang, Y. Cai, W. Wang,
L. Yang, et al. A conceptual model for the outbreak of coronavirus disease 2019 (covid-19)
in wuhan, china with individual reaction and governmental action. International journal
of infectious diseases, 2020.
[33] J. Liu, X. Liao, S. Qian, J. Yuan, F. Wang, Y. Liu, Z. Wang, F.-S. Wang, L. Liu, and
Z. Zhang. Community transmission of severe acute respiratory syndrome coronavirus 2,
shenzhen, china, 2020. Emerging infectious diseases, 26(6), 2020.
[34] C.

McClain

U.S.
tober,

Battles
2020.

and

L.

Rainie.

COVID-19
URL

|

Pew

The

Challenges

Research

Center.

of

Contact
Technical

Tracing
Report

as
Oc-

https://www.pewresearch.org/internet/2020/10/30/

the-challenges-of-contact-tracing-as-u-s-battles-covid-19/.
26

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[35] L. A. Meyers, B. Pourbohloul, M. E. Newman, D. M. Skowronski, and R. C. Brunham.
Network theory and sars: predicting outbreak diversity. Journal of theoretical biology,
232(1):71â€“81, 2005.
[36] I. F. Miller, A. D. Becker, B. T. Grenfell, and C. J. E. Metcalf. Disease and healthcare
burden of covid-19 in the united states. Nature Medicine, pages 1â€“6, 2020.
[37] Moderna. Modernaâ€™s covid-19 vaccine candidate meets its primary efficacy endpoint in
the first interim analysis of the phase 3 cove study. https://investors.modernatx.com/
node/10316/pdf, 2020. Accessed: 2020-12-10.
[38] A. Moinet, R. Pastor-Satorras, and A. Barrat. Effect of risk perception on epidemic
spreading in temporal networks. Physical Review E, 97(1):012313, 2018.
[39] J. MÃ¼ller, B. SchÃ¶nfisch, and M. Kirkilionis. Ring vaccination. Journal of Mathematical
Biology, 41(2):143â€“171, 2000. ISSN 03036812. doi: 10.1007/s002850070003.
[40] Nature Reviews Drug Discovery. Us authorization of first covid vaccine marks new phase
in safety monitoring. https://doi.org/10.1038/d41586-020-03542-4, 2020. Accessed:
2020-12-12.
[41] Nature Reviews Drug Discovery. The uk has approved a covid vaccine â€” hereâ€™s what scientists now want to know. https://www.nature.com/articles/d41586-020-03441-8,
2020. Accessed: 2020-12-12.
[42] Nature Reviews Drug Discovery. What chinaâ€™s speedy covid vaccine deployment means
for the pandemic. https://www.nature.com/articles/d41586-020-02807-2, 2020. Accessed: 2020-12-12.
[43] Nature Reviews Drug Discovery. Covid-19 vaccines buoy hope. https://www.nature.
com/articles/d41573-020-00215-9, 2020. Accessed: 2020-12-12.
[44] V. K. Nguyen, R. Mikolajczyk, and E. A. Hernandez-Vargas. High-resolution epidemic
simulation using within-host infection and contact data. BMC Public Health, 18(1), 2018.
ISSN 14712458. doi: 10.1186/s12889-018-5709-x.
[45] S. B. Omer, D. A. Salmon, W. A. Orenstein, M. P. Dehart, and N. Halsey. Vaccine
refusal, mandatory immunization, and the risks of vaccine-preventable diseases. New
England Journal of Medicine, 360(19):1981â€“1988, 2009.
[46] Oxford
covid-19

University.

Oxford

university

vaccine.

breakthrough

on

global

https://www.research.ox.ac.uk/Article/

2020-11-23-oxford-university-breakthrough-on-global-covid-19-vaccine,
2020. Accessed: 2020-12-10.
27

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[47] L. Peng, W. Yang, D. Zhang, C. Zhuge, and L. Hong. Epidemic analysis of COVID-19
in China by dynamical modeling. arXiv, feb 2020. URL http://arxiv.org/abs/2002.
06563.
[48] Pfizer Inc.
19

achieved

URL

Pfizer and biontech announce vaccine candidate against covidsuccess

in

first

interim

analysis

from

phase

3

study,

2020.

https://www.pfizer.com/news/press-release/press-release-detail/

pfizer-and-biontech-announce-vaccine-candidate-against.

Accessed:

2020-

12-10.
[49] V. K. Phadke, R. A. Bednarczyk, D. A. Salmon, and S. B. Omer. Association between
vaccine refusal and vaccine-preventable diseases in the united states: a review of measles
and pertussis. Jama, 315(11):1149â€“1158, 2016.
[50] C. L. Ricardo-Azanza and E. A. Vargas-Hernandez. The Risk of Lifting COVID-19
Confinement in Mexico. medRxiv, page 2020.05.28.20115063, jun 2020. doi: 10.1101/
2020.05.28.20115063. URL https://www.medrxiv.org/content/10.1101/2020.05.28.
20115063v1.
[51] A. Rizzo, B. Pedalino, and M. Porfiri. A network model for ebola spreading. Journal of
theoretical biology, 394:212â€“222, 2016.
[52] C. D. Russell, J. E. Millar, and J. K. Baillie. Clinical evidence does not support corticosteroid treatment for 2019-ncov lung injury. The Lancet, 395(10223):473â€“475, 2020.
[53] R. Sameni. Mathematical modeling of epidemic diseases; a case study of the covid-19
coronavirus. arXiv preprint arXiv:2003.11371, 2020.
[54] A. Sharma, S. N. Menon, V. Sasidevan, and S. Sinha. Epidemic prevalence information
on social networks mediates emergent collective outcomes in voluntary vaccine schemes.
arXiv preprint arXiv:1709.07674, 2017.
[55] A. Simha, R. V. Prasad, and S. Narayana. A simple stochastic sir model for covid 19 infection dynamics for karnataka: Learning from europe. arXiv preprint arXiv:2003.11920,
2020.
[56] R. Singh and R. Adhikari. Age-structured impact of social distancing on the covid-19
epidemic in india. arXiv preprint arXiv:2003.12055, 2020.
[57] United
tion.

States

Food

and

Drug

Authority.

Emergency

use

authoriza-

https://www.fda.gov/emergency-preparedness-and-response/

mcm-legal-regulatory-and-policy-framework/emergency-use-authorization,
2020. Accessed: 2020-12-10.
28

medRxiv preprint doi: https://doi.org/10.1101/2020.12.22.20248693; this version posted December 22, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

[58] D. J. Watts and S. H. Strogatz. Collective dynamics of â€˜small-worldâ€™networks. nature,
393(6684):440â€“442, 1998.
[59] J. S. Weitz, S. J. Beckett, A. R. Coenen, D. Demory, M. Dominguez-mirazo, J. Dushoff,
C.-y. Leung, G. Li, A. MÄƒgÄƒlie, S. W. Park, R. Rodriguez-gonzalez, S. Shivam, and C. Y.
Zhao. Modeling shield immunity to reduce COVID-19 epidemic spread. Nature Medicine,
2020. doi: 10.1038/s41591-020-0895-3.
[60] World
didate

Health

Organisation.

vaccines.

Draft

landscape

of

covid-19

can-

https://www.who.int/publications/m/item/

draft-landscape-of-covid-19-candidate-vaccines, 2020.

Accessed:

2020-12-

10.
[61] Z. Zaplotnik, A. Gavric, and L. Medic. Simulation of the covid-19 pandemic on the
social network of slovenia: estimating the intrinsic forecast uncertainty. arXiv preprint
arXiv:2005.13282, 2020.

29

